Sustainable production of radionuclidically pure antimony-119.

ABSTRACT:

Background

Radiopharmaceutical therapy (RPT) uses radionuclides that decay via one of three therapeutically relevant decay modes (alpha, beta, and internal conversion (IC) / Auger electron (AE) emission) to deliver short range, highly damaging radiation inside of diseased cells, maintaining localized dose distribution and sparing healthy cells. Antimony-119 (¹¹⁹Sb, t_1/2 = 38.19 h, EC = 100%) is one such IC/AE emitting radionuclide, previously limited to in silico computational investigation due to barriers in production, chemical separation, and chelation. A theranostic (therapeutic/diagnostic) pair can be formed with ¹¹⁹Sb's radioisotopic imaging analogue ¹¹⁷Sb (t_1/2 = 2.80 h, E_γ = 158.6 keV, I_γ = 85.9%,

SUBMITTER: Olson AP 

PROVIDER: S-EPMC11496484 | biostudies-literature | 2024 Oct

REPOSITORIES: biostudies-literature